SDGR - Schrodinger Inc Latest SEC Filings
This article provides the latest SEC filing information and detailed financial data for Schrodinger Inc (SDGR). It includes pricing, performance metrics, valuation ratios, insider and institutional ownership, profitability, and various technical indicators. The data highlights a recent closing price of $16.88 with a 2.99% change, along with key figures such as market cap, sales, and employee count.
Form 144 Schrodinger For: 1 July By Investing.com
The article "Form 144 Schrodinger For: 1 July" from Investing.com announces a Form 144 filing related to Schrodinger (SDGR). The publication provides general market data and news headlines, but specific details about the Form 144 filing or its implications for Schrodinger are not included in the provided text.
Enterprise value to EBIT forward of Schrodinger, Inc. – NASDAQ:SDGR
This article focuses on the enterprise value to EBIT forward for Schrodinger, Inc. (NASDAQ: SDGR). It provides a snapshot of this financial metric within the context of the company's profile on TradingView, indicating no current trades. The content primarily lists navigation and general information about TradingView's offerings rather than in-depth financial analysis.
Form 4 Schrodinger Inc For: 29 June By Investing.com
This article announces the filing of Form 4 for Schrodinger Inc. on June 29. It provides the financial details in summary and is primarily an announcement of this regulatory filing from Investing.com.
Schrodinger receives ~$57M cash payment after Eli Lilly acquisition of Ajax
Schrodinger (SDGR) has received a cash payment of approximately $57 million following Eli Lilly's acquisition of Ajax. The company is also eligible for additional cash payments based on Ajax achieving specific clinical and regulatory milestones. This information was disclosed under Regulation FD.
Price-Driven Insight from (SDGR) for Rule-Based Strategy
This article provides a price-driven analysis for Schrodinger Inc. (NASDAQ: SDGR) indicating strong near and mid-term sentiment but a weak long-term outlook. It identifies no resistance levels above the current price, suggesting upside potential. The analysis includes three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels.
Schrodinger, Inc. Actuals & Estimates (SWB:43Z)
This article provides financial actuals and estimates for Schrodinger, Inc. (SWB:43Z), including income statement, balance sheet, and cash flow data, along with analyst predictions for future stock performance. It details past earnings and revenue figures, upcoming earnings dates, and current financial metrics such as EBITDA and employee count. The report also addresses frequently asked questions about the company's stock ticker, forecasts, historical prices, and dividend policy.
Schrodinger, Inc. Actuals & Estimates (NASDAQ:SDGR)
This article provides current financial data and analyst estimates for Schrodinger, Inc. (NASDAQ:SDGR). It covers recent stock performance, price targets, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, offering a comprehensive look at the company's financial health and market perception.
Schrodinger, Inc. Actuals & Estimates (DUS:43Z)
This article provides financial actuals and estimates for Schrodinger, Inc. (DUS:43Z), including analyst price targets, historical stock performance, and upcoming earnings dates. It highlights that the company's stock has a max estimate of 26.41 EUR and a min estimate of 11.45 EUR, and its next earnings report is scheduled for August 5, 2026. The report also details past earnings, revenue, net income, and current employee count.
SDGR Forecast — Price Target — Prediction for 2027
Schrodinger, Inc. (SDGR) has a current stock price of $16.14, with analysts forecasting a max estimate of $30.00 and a min estimate of $13.00. The company's stock has seen a 22.00% rise over the last month but a 22.27% decrease over the last year. SDGR is expected to release its next earnings report on August 5, 2026, with revenue and earnings details for the last quarter provided.
Schrodinger (NASDAQ: SDGR) director receives RSUs and stock option grant
Schrodinger, Inc. director Gary L. Ginsberg received new equity awards, including 8,141 restricted stock units (RSUs) and a stock option for 13,313 shares at an exercise price of $15.23 per share. Both awards, granted on June 22, 2026, will vest on the twelve-month anniversary of the grant date (or earlier if the next annual stockholder meeting occurs sooner), subject to continued service. Following these transactions, Ginsberg directly holds 25,388 shares of common stock, which includes the unvested RSUs.
Schrodinger | 4: Statement of changes in beneficial ownership of securities-Director GINSBERG GARY L
This document is a statement of changes in beneficial ownership of securities for Director GINSBERG GARY L at Schrodinger, as required by regulatory filings. It details the modifications in security holdings by this insider.
Form 4 Schrodinger Inc For: 23 June By Investing.com
This article announces the filing of a Form 4 for Schrodinger Inc. on June 23, with Investing.com as the source. It briefly mentions the company's stock performance (SDGR +4.46%) and indicates that no public comments have been made on the filing. The rest of the content is filled with generic market data and site navigation.
Schrodinger (NASDAQ: SDGR) director receives RSU and stock option grants
Schrodinger, Inc. director Rosana Kapeller-Libermann was granted 8,141 restricted stock units (RSUs) and stock options for 13,313 shares. The RSUs and options, issued under the 2022 Equity Incentive Plan, vest over twelve months, contingent on continued service. Following these awards, Kapeller-Libermann directly holds 25,388 common shares, including the unvested RSUs.
Schrodinger (SDGR) director receives 8,141 RSUs and 13,313 stock options
Schrodinger, Inc. director Arun Oberoi has been granted 8,141 restricted stock units (RSUs) and 13,313 stock options as compensation under the company's 2022 Equity Incentive Plan. Both the RSUs and options were granted on June 22, 2026, and are set to vest on their twelve-month anniversary or earlier if the next annual stockholder meeting occurs sooner, contingent on continued service. Following these transactions, Oberoi directly holds 25,388 shares of common stock, including the unvested RSUs, with the stock options having an exercise price of $15.23 per share and expiring in 2036.
Form 4 Schrodinger Inc For: 23 June By Investing.com
This article announces the filing of Form 4 for Schrodinger Inc. (SDGR) on June 23. It provides limited detail beyond the announcement itself, embedded within a financial news portal that also displays various market data and related articles.
Schrodinger, Inc. (SDGR) director granted RSUs and stock options
Schrodinger, Inc. director Bridget A. van Kralingen was granted 8,141 restricted stock units (RSUs) and 13,313 stock options. These equity awards, made under the company's 2022 Equity Incentive Plan, vest on the 12-month anniversary of the June 22, 2026 grant date or earlier if the next annual stockholder meeting occurs before then. The stock options have an exercise price of $15.23 per share and expire on June 22, 2036.
Schrodinger (NASDAQ: SDGR) director granted RSUs and stock options in new Form 4
Schrodinger, Inc.'s director, Gary Sender, received compensation in the form of 8,141 restricted stock units (RSUs) and stock options for 13,313 shares. These equity awards, granted on June 22, 2026, are part of the company's 2022 Equity Incentive Plan and will vest after approximately one year, subject to continued service. Following these grants, Sender beneficially owns 25,388 common shares, including unvested RSUs, and the new option award.
Schrodinger (SDGR) grants RSUs and stock options to director Nancy Thornberry
Schrodinger, Inc. director Nancy Thornberry received new equity awards, including 8,141 restricted stock units (RSUs) and options for 13,313 shares at an exercise price of $15.23. These awards, granted on June 22, 2026, vest over a twelve-month period or sooner if the next annual stockholder meeting occurs earlier, subject to her continued service. The RSUs' settlement is deferred until separation from service or a change in control event, while the options expire on June 22, 2036.
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Morgan Stanley has maintained an "Equal Weight" rating on Schrödinger, Inc. (SDGR) but lowered its price target to $17 from $19. Schrödinger, Inc. reaffirmed its full-year guidance for ACV of $218 million to $228 million and projects 10-15% growth over 2025, along with the release of its AI co-scientist "Bunsen" this summer. The article also suggests that while SDGR has potential, other AI stocks may offer greater upside and less risk.
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Morgan Stanley has reiterated an "Equal Weight" rating on Schrödinger, Inc. (SDGR) but lowered its price target to $17 from $19. Schrödinger, a provider of chemical simulation software to the pharmaceutical industry, has maintained its full-year guidance for ACV and expects 10-15% growth over 2025. The company also announced plans to release its AI co-scientist "Bunsen" this summer.
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Morgan Stanley has maintained an "Equal Weight" rating on Schrödinger, Inc. (NASDAQ:SDGR) while lowering its price target to $17 from $19. The company provided full-year guidance for ACV of $218 million to $228 million and plans an early access release of its AI co-scientist "Bunsen" this summer. Schrödinger specializes in chemical simulation software for the pharmaceutical industry, and the article notes that while SDGR has potential, other AI stocks might offer higher returns in a shorter timeframe.
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On
This article highlights some of the top AI drug discovery stocks that hedge funds are investing in. It specifically focuses on Schrödinger, Inc. (NASDAQ:SDGR), detailing its financial guidance, a recent analyst rating, and its upcoming AI co-scientist launch. The company, which provides chemical simulation software and works in drug discovery, expects significant growth in its ACV and plans to release its "Bunsen" AI system this summer.
What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?
Schrodinger Inc (SDGR) is highlighted as a promising long-term investment, backed by 31 hedge funds including Bill & Melinda Gates Foundation Trust. The company recently transitioned to a hosted software licensing model, showing a 12% YoY increase in annual contract value (ACV) in Q1 2026, driven by new deployments. Schrodinger projects 2026 ACV between $218 million and $228 million, and drug discovery revenue between $55 million and $65 million, with Lilly's acquisition of Ajax Therapeutics validating their platform's strength.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. announced inducement grants on June 12, 2026, awarding restricted stock units (RSUs) for 10,771 shares to seven new employees. These grants were made under the company's 2021 Inducement Equity Incentive Plan as a material inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% vesting after 12 months and the remainder in equal yearly installments over the subsequent three years.
(SDGR) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of Schrodinger Inc. (NASDAQ: SDGR) stock, highlighting strong near and mid-term sentiment but a weak long-term outlook. It presents three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths, support, and resistance levels.
Schrodinger Inc (SDGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Schrodinger Inc (SDGR) across its various business segments and geographical regions. It highlights that on-premise software and drug discovery services are the largest contributors to revenue, while the United States and EMEA regions account for the majority of geographical revenue. The data is presented for fiscal year 2023, with updates as of April 6.
Schrodinger Inc (SDGR) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Schrodinger Inc (SDGR), noting its current earnings forecast score is 8.00, ranking 112th in the Software & IT Services industry. Analysts project an average price target of $28.00, with a consensus "Buy" rating based on 8 analysts. Expected revenue for the next quarter is $48.08 million, and EPS is predicted to be -$0.61.
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)
Two healthcare companies, Schrodinger (SDGR) and Climb Bio (CLYM), received bullish sentiments from analysts. Matt Hewitt from Craig-Hallum maintained a Buy rating on Schrodinger with an average price target of $18.80, while William Blair analyst Matt Phipps reiterated a Buy rating on Climb Bio, which has a Strong Buy consensus and a price target of $22.44, representing a 109.3% upside.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) reported a wider-than-expected loss for the first quarter of 2026, while also missing revenue estimates. The company posted a loss of $0.66 per share, compared to the Zacks Consensus Estimate of a $0.57 per share loss, and revenue of $42.6 million, falling short of the $43.9 million projection. Management reaffirmed its full-year 2026 revenue guidance.
Schrödinger Finalizes Transition Terms for Former Commercial Chief
Schrödinger, Inc. has finalized a transition agreement with its former Chief Commercial Officer, Mannix Aklian, formalizing a previous leadership change. The agreement includes salary continuation for nine months, subsidized health coverage, bonus payments totaling $88,096, and accelerated vesting of stock units in exchange for customary releases and restrictive covenants. This move aligns with Schrödinger's governance practices and aims to minimize operational disruption during the leadership transition.
Schrodinger finalizes separation agreement with former chief commercial officer
Schrodinger, Inc. (NASDAQ:SDGR) has finalized a transition and separation agreement with its former Chief Commercial Officer, Mannix Aklian, following his departure from the company. The agreement outlines severance payments, COBRA premiums, and prorated bonuses totaling $88,096, along with accelerated vesting of some restricted stock units. Additionally, the agreement includes mutual releases of claims and ongoing confidentiality obligations for Mr. Aklian.
Schrodinger separation of Mannix Aklian as Chief Commercial Officer confirmed
Schrodinger (SDGR) has confirmed the separation of Mannix Aklian from his role as Chief Commercial Officer, Global Head of Software Sales and Marketing. The company detailed a separation agreement outlining specified payments and benefits. This change was effective June 5, 2026, following a previously disclosed separation.
Severance package for ex-commercial chief at Schrödinger (NASDAQ: SDGR)
Schrödinger, Inc. (NASDAQ: SDGR) has detailed the separation terms for its former Chief Commercial Officer, Mannix Aklian, which align with his previous employment and severance agreements. Aklian will receive nine months of base-salary continuation, up to 12 months of company-paid COBRA premiums, and cash bonuses totaling $88,096 before taxes for quarters worked in 2026. Additionally, a portion of his July 2026 restricted stock unit tranche will see accelerated vesting, with all benefits contingent on his non-revocation of the agreement and adherence to ongoing confidentiality and non-solicitation obligations.
Schrodinger finalizes separation agreement with former chief commercial officer
Schrodinger, Inc. (NASDAQ:SDGR) has finalized a separation agreement with its former Chief Commercial Officer, Mannix Aklian, outlining the terms of his departure. The agreement includes salary continuation, COBRA premiums, various bonus payments totaling $88,096, and accelerated vesting of some restricted stock units. Additionally, the company recently reported mixed Q1 2026 earnings and an analyst report highlighted AI's potential to significantly reduce drug development costs.
(SDGR) as a Liquidity Pulse for Institutional Tactics
This article from Stock Traders Daily provides an AI-driven analysis of Schrodinger Inc. (NASDAQ: SDGR), highlighting mixed sentiment and suggesting choppy conditions. It presents three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, indicating varying support and resistance levels.
10 Top Tech Companies in Munich
Munich has established itself as a premier tech hub in Europe, driven by a highly skilled workforce and a stable business economy. The city's tech scene encompasses AI, robotics, cybersecurity, medtech, and autonomous mobility. Prominent academic institutions like the Technical University of Munich regularly supply the ecosystem with technical talent.
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026 - News and Statistics
This article compares Recursion Pharmaceuticals and Schrodinger, two companies employing different strategies in drug discovery, in 2026. Recursion relies on AI and extensive data within a biotech-heavy model, while Schrodinger uses a physics-based computational platform for molecular modeling. The article provides financial highlights for both companies in fiscal 2025, noting Recursion's higher revenue growth but larger net loss, and Schrodinger's lower revenue growth but significantly improved net loss and positive free cash flow, offering insights for investors considering either a biotech or software-focused approach.
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook?
Schrödinger, Inc. (SDGR) recently reaffirmed its 2026 financial guidance despite the departure of its Chief Commercial Officer, Mannix Aklian, and the interim appointment of Paul Davie. This move prompts questions about the company's commercial strategy amidst consistent financial forecasts. The article explores how this change could impact Schrödinger's investment narrative, particularly concerning software adoption and partnerships.
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook?
Schrödinger, Inc. (SDGR) recently reaffirmed its Q2 and full-year 2026 financial guidance while simultaneously announcing the departure of its Chief Commercial Officer, Mannix Aklian, and the appointment of an interim CCO. This leadership change, coupled with steady financial projections, raises questions about the company's commercial strategy and potential shifts in its go-to-market execution. Investors are urged to consider how this move might impact the company's dependency on software adoption, milestone revenue, and concentrated software revenue given ongoing margin pressures.
Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq
Schrodinger Inc. (SDGR) shares have continued their late-May rebound on Nasdaq, trading around the mid-teens. The stock saw a 7.3% intraday rise on May 29, 2026, and gained approximately 14.3% over the week and 29.3% over the month ending May 29, 2026. This performance has reignited investor interest in the company's computational drug discovery software and biotechnology business, particularly after its latest quarterly results for the period ended March 31, 2026, were released on May 8, 2026.
Schrödinger, Inc. Hits Day High with Strong 7.34% Intraday Surge
Schrödinger, Inc. stock saw a significant intraday surge of 7.34%, reaching USD 15.43, and has shown strong weekly and monthly gains. Despite this recent positive momentum, the company faces long-term challenges, including a 14.99% decline year-to-date and a 57.78% drop over the past three years. Financial indicators like negative return on equity and low operating cash flow also highlight ongoing underperformance compared to the S&P 500.
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth
Schrödinger (NASDAQ:SDGR) is highlighted as a company in a strong financial position to invest in growth, despite having recently posted negative earnings. The article examines its balance sheet, noting a significant cash reserve and minimal debt, which contrasts with its current unprofitability. This financial strength positions Schrödinger to fund research and development or strategic acquisitions, making it an interesting prospect for investors looking for growth opportunities.
SDGR Financials: Revenue Breakdown, Margins & Competitor Comparison
Schrodinger Inc (SDGR) generates revenue primarily from drug discovery services, which account for 39.1% of its total sales, amounting to $22.88M, with other significant streams including on-premise and hosted software. The company shows a gross margin of 50.43% but has negative operating and net margins, indicating challenges in profitability. SDGR competes with companies like INNV and RZLV, holding a strong market position with a $1.06B market capitalization, and its gross margin compares favorably to INNV's.
(SDGR) Risk Channels and Responsive Allocation
The article provides a detailed analysis of Schrodinger Inc. (NASDAQ: SDGR), highlighting a positive near-term sentiment that may shift due to broader weak alignment and a mid-channel oscillation pattern. It outlines exceptional short setup risk-reward ratios and various AI-generated trading strategies for different risk profiles. The analysis includes multi-timeframe signals, support, and resistance levels for optimal positioning.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) announced inducement grants made on May 18, 2026, to new employees under its 2021 Inducement Equity Incentive Plan. These grants included non-statutory stock options for 1,875 shares to one employee and restricted stock units (RSUs) for 18,766 shares to seven employees, as a material inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $12.05 and vest over four years, while the RSUs also vest over four years.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) announced inducement grants made on May 18, 2026, to new employees. These include non-statutory stock options for 1,875 shares to one employee and restricted stock units (RSUs) for 18,766 shares to seven employees. These grants were part of their compensation packages under the company's 2021 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. announced inducement grants to recently hired employees on May 18, 2026, including stock options for one employee and restricted stock units (RSUs) for seven employees. These grants, made under the company's 2021 Inducement Equity Incentive Plan, serve as a material inducement for their employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants feature four-year vesting schedules for both the stock options and RSUs.
Schrodinger (SDGR) Issues Stock Options and RSUs to New Employees
Schrodinger Inc (SDGR) has announced the issuance of stock options and restricted stock units (RSUs) to new employees as part of its talent attraction and retention strategy. This move, compliant with Nasdaq Listing Rules, involved granting options for 1,875 shares and RSUs for 18,766 shares that vest over four years. While the company exhibits strong growth potential with a GF Score of 66/100, concerns exist regarding its profitability, financial strength, and recent insider selling of $1.3 million.
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Schrödinger (SDGR) announced inducement grants in compliance with Nasdaq Listing Rule 5635(C)(4). The grants were reported by Refinitiv and are part of the company's regulatory disclosures. The article is very brief and directs readers to log in for more details.
